PHARMA WISDOM

PHARMA WISDOM

Pharma, Life Science, Healthcare, Engineering Job Updates

Recent Updates

Thursday 19 November 2015

Pharm.D 1st Year REGULAR / SUPPLEMENTARY Examination Previous Question Papers - JNTU HYDERABAD

19:31:00 13



HUMAN ANATOMY AND PHYSIOLOGY - Click Here

PHARMACEUTICS - Click Here

MEDICINAL BIOCHEMISTRY - Click Here

PHARMACEUTICAL ORGANIC CHEMISTRY- Click Here

                 PHARMACEUTICAL INORGANIC CHEMISTRY- Click Here

REMEDIAL  MATHEMATICS- Click Here


Categories: 
JNTUH (Jawaharlal Nehru Technological University Hyderabad)

Posted  by PHARMA WISDOM
Leave a comment
For more Updates, follow us on Facebook. 
Happy Blogging...!!!
Read More
Posted by at 13 comments:
Labels:

Tuesday 17 November 2015

DARZALEX (daratumumab) Approved by U.S. FDA

19:25:00 0
DARZALEX (daratumumab) Approved by U.S. FDA: First Human Anti-CD38 Monoclonal Antibody Available for the Treatment of Multiple Myeloma.

Release date- 16112015 - HORSHAM, PA, - Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, announced today the U.S. Food and Drug Administration (FDA) has approved DARZALEX (daratumumab) injection for intravenous infusion for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.1
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Multiple myeloma is an incurable blood cancer that occurs when malignant plasma cells grow uncontrollably in the bone marrow.2,3 Refractory cancer occurs when a patient's disease is resistant to treatment or in the case of multiple myeloma, the disease progresses within 60 days of their last therapy.4,5 Relapsed cancer means the disease has returned after a period of initial, partial or complete remission.6
DARZALEX is the first human anti-CD38 monoclonal antibody (mAb) approved anywhere in the world. CD38 is a surface protein that is expressed by most, if not all, multiple myeloma cells.7 DARZALEX is believed to induce tumor cell death through multiple immune-mediated mechanisms of action,8,9 in addition to apoptosis, in which a series of molecular steps in a cell lead to its death.10 Its approval comes just two months after the Biologics License Application (BLA) was accepted for Priority Review by the FDA in September 2015.11 DARZALEX received Breakthrough Therapy Designation from the FDA for this indication in May 2013.12
'Multiple myeloma is a highly complex disease and remains incurable, with almost all patients relapsing or becoming resistant to therapy,' said DARZALEX clinical trial investigator Paul G. Richardson, M.D., Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute. 'With DARZALEX, we have a promising new immunotherapy, which has shown pronounced efficacy as a single agent with an acceptable adverse event profile. This is especially important for treating these heavily pre-treated patients in whom all of the major classes of currently available medicines have failed.'

'Living with multiple myeloma is challenging, both physically and emotionally, especially as the disease progresses and treatment options become more limited,' said Debby Graff, a patient enrolled in a clinical trial at Dana-Farber Cancer Institute. 'I am encouraged by emerging treatments for multiple myeloma, and I have a new outlook on my path forward.'
'While there have been considerable improvements over the past decade in the treatment of people living with multiple myeloma, these patients face a long, hard road - especially those whose disease has relapsed or is no longer responding to current therapies,' said Walter M. Capone, President and Chief Executive Officer of the Multiple Myeloma Research Foundation (MMRF). 'With the approval of daratumumab, a new antibody option targeting CD38, along with ongoing work to advance the development of novel classes of therapies by both Janssen and MMRF, we are ushering in a new era of myeloma therapy focused on individualized treatment approaches for patients with significant unmet needs.'
'Our focus is developing transformational medicines for people living with hard-to-treat cancers, such as multiple myeloma,' said Peter F. Lebowitz, M.D., Ph.D., Global Oncology Head, Janssen. 'The rapid development and approval of DARZALEX - the first human anti-CD38 monoclonal antibody - is a great example of this commitment and our ongoing work in developing immunotherapies. We will continue to study this compound as both a mono- and a combination therapy to understand its full clinical benefit for patients across the treatment continuum in multiple myeloma and other tumor types.'
The warnings and precautions for DARZALEX include infusion reactions, interference with serological testing and interference with determination of complete response (see Important Safety Information).1 The most frequently reported adverse reactions (incidence =20%) were: fatigue, nausea, back pain, pyrexia, cough and upper respiratory tract infection.1
In data from three pooled clinical studies including a total of 156 patients, four percent of patients discontinued treatment due to adverse reactions.1 Infusion reactions were reported in approximately half of all patients treated with DARZALEX.1 Common (=5 percent) symptoms of infusion reactions included nasal congestion, chills, cough, allergic rhinitis, throat irritation, dyspnea (shortness of breath) and nausea.1 Severe infusion reactions, including bronchospasm, dyspnea, hypoxia and hypertension.
Source: http://www.pharmacychoice.com


For more Updates, follow us on Facebook. 
Happy Blogging...!!!
Read More
Posted by at No comments:
Labels:

Drug promises robust new hair growth

19:10:00 0
A new method of restoring hair growth - using drugs that are already approved for safety - may be on the way, according to research published in Science Advances.
Researchers at Columbia University Medical Center in New York have found that when hair follicles are suspended in a resting state, rapid and robust growth can be restored by inhibiting a family of enzymes inside the follicles.
Hair follicles do not produce hair constantly but rather cycle between four resting and growing phases.
More than 90% of the hair is normally in the growing phase, "anagen," which can last from 2-6 years.
The relatively short catagen phase follows, when the follicle regresses and moves toward the surface. "Telogen" is the resting phase, and "exogen" is when the hair falls out before the follicle resumes growth.
Generally, the longer the hair, the longer the phases are; long hair tends to grow more slowly.


Enzyme inhibitors promote growth:
In experiments with normal mouse and human hair follicles, Dr. Angela Christiano, PhD, and colleagues found that drugs that inhibit the Janus kinase (JAK) family of enzymes promote rapid and robust hair growth when directly applied to the skin.

Fast facts about male baldness
  • 95% of male baldness is due to androgenetic alopecia
  • By age 35, 2 in 3 men in the US will have noticeable hair loss
  • In 25% of men, hair loss begins before age 21.
This suggests that JAK inhibitors could be used to restore hair growth in various forms of hair loss, such as that induced by male pattern baldness - also called androgenetic alopecia - and other types of hair loss that occur when hair follicles are trapped in a resting state.
Two JAK inhibitors have already been approved by the US Food and Drug Administration (FDA), one for treatment of blood diseases (ruxolitinib) and the other for rheumatoid arthritis (tofacitinib).
Both are being tested in clinical trials for the treatment of plaquepsoriasis and alopecia areata, an autoimmune disease that attacks the follicles, causing hair loss.
It was while studying alopecia areata that the researchers chanced upon the effect of JAK inhibitors on hair follicles.
They had already found that JAK inhibitors shut off the signal that causes the autoimmune attack, and that oral forms of the drug restore hair growth in some people with the disorder.
Source:medicalnewstoday.com
For more Updates, follow us on Facebook. 

Happy Blogging...!!!
Read More
Posted by at No comments:
Labels:

Wednesday 30 September 2015

67th INDIAN PHARMACEUTICAL CONGRESS

23:11:00 1

67th INDIAN PHARMACEUTICAL CONGRESS

                   19-21 December, 2015

ONLINE SUBMISSION DATES

Start Date: dateicon  01-08-2015
Last Date: dateicon  10-10-2015

ANNOUNCEMENT OF ACCEPTANCE

31 OCTOBER 2015


CONFERENCE HOST

dateicon
Indian Hospital Pharmacist Association(IHPA)
| Venue
   JSS University, Mysore

Conference Highlights
Pharma industry
Pharma Education
students
Hospital and Community Practice
Students
Read More
Posted by at 1 comment:
Labels:

Thursday 17 September 2015

Public Health : 100 Global Health issues

13:42:00 5
Today, I would like to list out 100 important global health issues that are covered under Public health.
I have come across many students making fun of Public health, when asked what is public health they say.. "it is health of public and why you are asking it when it is so simple". Let me add few points for their innocence.

What is Public health?

Public health refers to all organized measures to prevent disease, promote health, and prolong life among the population as a whole. Its activities aim to provide conditions in which people can be healthy and focus on entire populations, not on individual patients or diseases. Thus, public health is concerned with the total system and not only the eradication of a particular disease. 

The three main public health functions are:
  • The assessment and monitoring of the health of communities and populations at risk to identify health problems and priorities.
  • The formulation of public policies designed to solve identified local and national health problems and priorities.
  • To assure that all populations have access to appropriate and cost-effective care, including health promotion and disease prevention services.
Public health is all around us: the water we drink, the immunizations we receive and the environment in which we live in..  


List of various Global health issues covered under Public Health:
  1. Adolescent health
  2. Ageing
  3. Bacterial diseases
  4. Biological issues
  5. Biosafety
  6. Blood transfusion safety and blood products
  7. Cancer
  8. Cardiovascular diseases
  9. Chemical Safety
  10. Child and Maternal health
  11. Communicable diseases
  12. Diabetes
  13. Diarrhoeal diseases and Cholera
  14. Disabilities and Rehabilitation
  15. eHealth
  16. Emergency and Humanitarian action
  17. ePortuguese programme 
  18. Environmental and Humanitarian action / hazards
  19. Ethics
  20. Event based surveillance 
  21. Evidence informed policy making
  22. Filarial infections
  23. Finance
  24. Food safety
  25. Gender, Women and Health
  26. General management
  27. Genetics and hereditary diseases
  28. Global health observatory
  29. Global Learning and performance management
  30. Global mass gathering
  31. Health economics and financing
  32. Health information, statistics, measurement and trend assessment 
  33. Health legislation and human rights
  34. Health promotion and education
  35. Health security
  36. Health systems research and development
  37. Health technology (laboratory services)
  38. Healthy cities
  39. Hepatitis
  40. HIV/AIDS
  41. Human Resources management
  42. Human resources for health (excluding Nursing)
  43. Immunology
  44. Influenza
  45. Informatics and telemedicine
  46. Information technology and telecommunications
  47. Injuries, violence and accident prevention
  48. International health regulations
  49. Laboratory biorisk management
  50. Laboratory biosecurity
  51. Legal
  52. Leishmaniasis
  53. Leprosy
  54. Library services and publishing
  55. Malaria
  56. Mental health and Neurosciences
  57. Monitoring and Evaluation
  58. Non-communicable diseases
  59. Nursing
  60. Nutrition
  61. Occupational health
  62. Oral health
  63. Organ transplantation
  64. Outbreak alert and response
  65. Parasitic diseases
  66. Patient safety
  67. Pharmaceuticals (Essential drugs and Medicines)
  68. Planning, Resource coordination and Performance monitoring 
  69. Poliomyelitis
  70. Prevention of Blindness
  71. Prevention of Deafness
  72. Public Health Emergency
  73. Rabies
  74. Radiation
  75. Reproductive health
  76. Research policy and development
  77. Respiratory infections
  78. Rheumatic diseases
  79. Risk assessment
  80. Risk communication
  81. Safety measures in Microbiology
  82. Schistosomiasis
  83. Security management
  84. Sexual Transmitted Diseases
  85. Small pox
  86. Social determinants of health
  87. Suicide prevention
  88. Substance abuse (alcohol and drugs)
  89. Surgical care
  90. Tobacco
  91. Tourist health and travel medicine
  92. Traditional medicine
  93. Trypanosomiasis
  94. Tuberculosis
  95. Vaccines
  96. Vector biology and control
  97. Viral diseases
  98. Viral hemorrhagic fevers
  99. Water and sanitation
  100. Zoonoses.
For more Updates, follow us on Facebook. 

Happy Blogging...!!!
Read More
Posted by at 5 comments:
Labels:

Every 7 seconds one person dies from Diabetes : How to prevent it

13:42:00 0
World Diabetes Day (WDD) is celebrated annually on November 14. Led by the International Diabetes Federation (IDF), World Diabetes Day was created in 1991 by IDF and the World Health Organization in response to growing concerns about the escalating health threat posed by diabetes.


Global Burden : Interesting facts
  1. The human and economic burden of diabetes is enormous: it affects almost 400 million people, results in over 5 million deaths annually and consumes almost US$ 550 billion in health related expenditures.
  2. The majority of the costs related to diabetes are spent on treating complications, which can affect the heart, eyes, kidneys and feet; these complications can be prevented through early diagnosis and proper management of diabetes.
  3. Delayed diagnosis means that many people already have at least one complication by the time they are diagnosed with diabetes.
  4. Over 70% of type 2 diabetes cases can be prevented or delayed by adopting healthier lifestyles, equivalent to up to 150 million cases by 2035.
  5. Eating a healthy breakfast decreases the risk of developing type 2 diabetes.
  6. A healthy diet containing leafy vegetables, fresh fruit, whole grains, lean meat, fish and nuts can help reduce a person’s risk of type 2 diabetes and avoid complications in people with diabetes.
  7. Skipping breakfast is associated with weight gain, one of the main risk factors for type 2 diabetes. Overweight and obesity account for up to 80% of new cases of type 2 diabetes.
  8. Reducing the prevalence of type 2 diabetes will result in an increased participation and productivity in the workforce, given that the greatest number of people with diabetes are between 40 and 59 years of age.
  9. Diabetes accounts for 10-15% of the total healthcare budgets in high income countries. 1 in 9 healthcare US$ is spent on diabetes.
  10. Up to 11% of total healthcare expenditure in every country across the globe could be saved by tackling the preventable risk factors for type 2 diabetes.
Know how to prevent it: 


For more Updates, follow us on Facebook. 

Happy Blogging...!!!
Read More
Posted by at No comments:
Labels: